See more : Sanderson Farms, Inc. (SAFM) Income Statement Analysis – Financial Results
Complete financial analysis of Theradiag SA (ALTER.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theradiag SA, a leading company in the Medical – Devices industry within the Healthcare sector.
- Silverlake Axis Ltd (SLVFF) Income Statement Analysis – Financial Results
- I2PO Société anonyme (I2PO.PA) Income Statement Analysis – Financial Results
- Oracle Financial Services Software Limited (OFSS.NS) Income Statement Analysis – Financial Results
- MONIND LIMITED (MONIND.BO) Income Statement Analysis – Financial Results
- Tan Chong International Limited (0693.HK) Income Statement Analysis – Financial Results
Theradiag SA (ALTER.PA)
About Theradiag SA
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.20M | 11.12M | 10.41M | 9.64M | 8.91M | 9.06M | 8.98M | 7.56M | 7.11M | 6.76M | 8.25M | 10.15M |
| Cost of Revenue | 6.74M | 6.28M | 5.51M | 5.03M | 4.11M | 4.93M | 4.65M | 4.88M | 5.04M | 4.37M | 4.71M | 7.06M |
| Gross Profit | 5.47M | 4.84M | 4.91M | 4.61M | 4.80M | 4.13M | 4.33M | 2.68M | 2.08M | 2.39M | 3.54M | 3.09M |
| Gross Profit Ratio | 44.81% | 43.52% | 47.11% | 47.84% | 53.85% | 45.62% | 48.23% | 35.46% | 29.21% | 35.34% | 42.95% | 30.47% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 457.90K | 1.43M | 1.42M | 1.48M | 1.52M | 1.16M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.62M | 4.70M | 4.63M | 4.47M | 4.39M | 5.53M | 5.36M | 5.21M | 4.80M | 4.13M | 3.50M | 0.00 |
| Other Expenses | 5.75M | 5.72M | 5.50M | 4.51M | 5.36M | 6.65M | 6.55M | 6.09M | 5.27M | -10.00K | 4.52M | 3.68M |
| Operating Expenses | 5.75M | 5.72M | 5.50M | 4.51M | 5.36M | 6.65M | 6.55M | 6.09M | 5.27M | 4.36M | 4.52M | 3.68M |
| Cost & Expenses | 12.48M | 12.00M | 11.01M | 9.54M | 9.47M | 11.57M | 11.20M | 10.97M | 10.31M | 8.73M | 9.23M | 10.74M |
| Interest Income | 3.91K | 3.86K | 21.00 | 12.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90K | 36.08K | 7.72K |
| Interest Expense | 87.74K | 63.94K | 67.37K | 60.59K | 62.92K | 69.12K | 76.68K | 90.19K | 79.84K | 64.98K | 78.41K | 80.43K |
| Depreciation & Amortization | 519.37K | 599.41K | 545.13K | 545.75K | 626.76K | 2.60M | 629.60K | 550.22K | 404.62K | 163.59K | 254.79K | 301.95K |
| EBITDA | 245.24K | -279.64K | 47.91K | 716.82K | 125.59K | 101.45K | -1.49M | -2.80M | -2.72M | -1.75M | -370.74K | -230.39K |
| EBITDA Ratio | 2.01% | -2.51% | 0.46% | 7.44% | 1.41% | 1.12% | -16.62% | -37.06% | -38.29% | -25.94% | -4.49% | -2.27% |
| Operating Income | -274.14K | -879.05K | -497.23K | 171.07K | -501.17K | -2.50M | -2.22M | -3.41M | -3.19M | -1.97M | -978.63K | -589.93K |
| Operating Income Ratio | -2.25% | -7.90% | -4.77% | 1.78% | -5.62% | -27.64% | -24.78% | -45.10% | -44.89% | -29.20% | -11.86% | -5.81% |
| Total Other Income/Expenses | -418.81K | -148.61K | -117.75K | 689.12K | -478.92K | -771.58K | -47.67K | -84.22K | -170.97K | -100.16K | -171.48K | 251.39K |
| Income Before Tax | -692.95K | -1.03M | -614.97K | 66.67K | -1.04M | -4.79M | -2.27M | -3.50M | -3.36M | -2.07M | -1.15M | -338.54K |
| Income Before Tax Ratio | -5.68% | -9.24% | -5.91% | 0.69% | -11.69% | -52.89% | -25.31% | -46.21% | -47.29% | -30.68% | -13.94% | -3.33% |
| Income Tax Expense | -205.37K | -260.70K | -383.92K | -282.23K | -254.40K | -335.87K | -189.04K | -621.89K | -542.42K | -159.69K | -178.37K | -274.23K |
| Net Income | -487.58K | -766.96K | -231.05K | 348.91K | -787.16K | -5.96M | -2.08M | -2.97M | -2.96M | -1.91M | -971.74K | -338.54K |
| Net Income Ratio | -4.00% | -6.89% | -2.22% | 3.62% | -8.83% | -65.78% | -23.21% | -39.21% | -41.67% | -28.32% | -11.77% | -3.33% |
| EPS | -0.04 | -0.06 | -0.02 | 0.04 | -0.08 | -0.63 | -0.28 | -0.44 | -0.53 | -0.42 | -0.24 | -0.01 |
| EPS Diluted | -0.04 | -0.06 | -0.02 | 0.04 | -0.08 | -0.63 | -0.28 | -0.44 | -0.53 | -0.42 | -0.24 | -0.01 |
| Weighted Avg Shares Out | 13.01M | 13.02M | 9.41M | 9.45M | 9.39M | 9.43M | 7.48M | 6.68M | 5.64M | 4.57M | 4.09M | 25.52M |
| Weighted Avg Shares Out (Dil) | 13.01M | 13.02M | 9.41M | 9.45M | 9.39M | 9.43M | 7.48M | 6.68M | 5.64M | 4.57M | 4.09M | 25.52M |
Source: https://incomestatements.info
Category: Stock Reports